A success in finding a commercial solution drug for Ebola would see significant demand from countries looking to build up stockpiles for a quicker response

BANGALORE, INDIA, October 8, 2015 /EINPresswire.com/ -- Medical experts are of the opinion that Ebola virus would soon reach America from Africa and it is just a matter of time. While the threat of the spread of Ebola is real, the fight to find out the appropriate medicine to combat it is on. Startup Biotech companies, like Tekmira Pharmaceuticals Corporation and Sarepta Therapeutics Inc and large drug makers like GlaxoSmithKline are developing new therapies that target the tough to treat disease.

Following the use of its experimental Ebola vaccine to treat a doctor that contracted the disease in Africa and returned to the United States for treatment, Tekmira drew a significant amount of media attention. The FDA granted permission for emergency use on Dr. Sacra and others who had contracted the disease and were struggling to overcome it. This was a rare occasion when the US drug agency granted such permission to Tekmira's therapy that was named TKM-Ebola.

The company managed to develop TKM-Ebola with a $140 million grants from the Department of Defense and it is not the only biotech company that has received money from the DoD to develop a vaccine.

$291 million from the DoD in 2010 was received from Sarepta Therapeutics for a potential treatment develop AVI-7537 for the possible treatment of Ebola. However, lack of funds forced the scrapping of the research. Sarepta is hopeful about future funding since AVI-7537 had a 60%-80% success rate in pre-clinical trials in monkeys.

GlaxoSmithKline, one of the globe's biggest drug makers is also conducting research to find out a commercial cure and prevention of Ebola. Another early stage Ebola vaccine that has shown promise in pre-clinical trials are being worked upon by GlaxoSmithKline along with the National Institutes of Health.

Glaxo is currently studying the vaccine in volunteers in the U.S. and U.K. in a small phase 1 trial and is creating up to 10,000 doses of the vaccine for emergency use, such as for healthcare workers helped by funding from the Wellcome Trust, Medical Research Council and the U.K. government.

Researchers should have a better handle on efficacy over time, even as Tekmira and Glaxo's respective vaccines are being tested in humans.

A success in finding a commercial solution drug for Ebola would see significant demand from countries looking to build up stockpiles so that the response to future outbreaks can be quicker.

For more market research reports on Biotechnology Industry Visit
https://literated.com/industry/Biotechnology-Industry

About Literated.com
Literated.com is a one stop market research and e-commerce platform catering to the needs of businesses and knowledge workers who are dependent on market research information for their work.
Visit https://literated.com for more info.

Sachidanand Bhat
Literated.com
8971520970
email us here